C O M M U N I C A T I O N S
Scheme 3 a
Figure 2. A proposed mechanism for conversion of 11d to 11a.
To avoid this side reaction, direct treatment of (4S)-2 with free
peptide 3a was employed, successfully affording the expected
compound 1a (25% after purification by HPLC). The spectroscopic
data of 1a match those reported for the natural sample. To confirm
these results, reaction of rac-2 with free peptide 3a was also
examined, giving a 1:1 mixture of 1a and 14. The 1H NMR
spectrum of this mixture showed distinct chemical shift differences
in the chromophore region as comparison to pure 1a (see Supporting
Information). On the basis of the above evidence, the configuration
of the chlorofusin chromophore1 was revised as (4S,8R,9S)-1a.
In summary, the first total synthesis of chlorofusin was ac-
complished in a convergent fashion. By comparison with all four
unambiguous diastereomeric model chromophores, the absolute
stereochemistry of the chlorofusin chromophore was finally deter-
mined as (4S,8R,9S). This allows the complete structure of natural
chlorofusin to be assigned for the first time. The enantioselective
copper-mediated oxidation of 4 followed by mild coupling of
azaphilone 2 with the amine-bearing cyclopeptide 3 in a cascade
fashion, and a final one-pot spiro-aminal formation were achieved
with high efficiency to yield the correct stereochemical product.
Further biological evaluation of chlorofusin and its isomers, as well
as synthetic model chromophores, are underway in this laboratory
and will be reported in due course.
a Reaction conditions: (a) NBS, CH3CN, room temp; (b) MeNH2HCl,
aq NaHCO3, CH3CN, room temp; (c) Ag2O, MeCN, room temp, 70% (11a:
11b:11c:11d )1:1:2.5:4, by HPLC analysis).
Scheme 4 a
a Reaction conditions: (a) (4S)-2 and 3a or 3b, same conditions as in
i
Scheme 3; (b) TFA-H2O (10: 1), Pr3SiH (2 equiv), room temp.
cation and subsequent in situ mild hydrolysis serve as the key
reactions to quickly generate a hydroxylated spiro aminal. Using
rac-2 and rac-10 as substrates, various conditions were examined
(Scheme 3). In most cases, all four possible products (11a-d)
were generated in different yields and ratios. These four sep-
arable compounds were unambiguously characterized by X-ray
single crystal analyses.6a By comparison of NMR data, 11d
was found to be the closest to the chromophore of chlorofusin
(see the Supporting Information). This indicated that the orig-
inally proposed stereochemical assignment for the chromophore
might need to be revised. To confirm our initial findings, work
focused on the synthesis of 11d. Eventually, one-pot se-
quential treatment of rac-2 in MeCN with NBS, MeNH2, and Ag2O
was found to work best, both in terms of the product ratio and-
the overall yield. This sequential treatment protocol greatly re-
duced the complexity of handling a complex molecule as
large as chlorofusin and presented the advantage of ease of
operation.
Encouraged by these results, coupling of (4S)-2 with peptide 3b
was initially attempted using a sequential protocol, giving the
expected compound 12 in 23% yield (Scheme 4). Unfortunately,
final trityl-deprotection using TFA-H2O (10:1) in the presence of
iPr3SiH (2 equiv) afforded the unexpected stereoisomer of chloro-
fusin, 13 (80%). Evidently, the spiro aminal in 12 opened and
reformed under the acidic conditions used. This was confirmed
when it was shown that rac-11d could be fully converted to rac-
11a under similar conditions (detection by HPLC). A mechanism
was proposed in Figure 2.
Acknowledgment. This project is financially supported by the
NSFC (Grants 20425205, 20432020, 20621062), CAS (Grant
KJCX2-YW-H08), and SHMCST (Grants 06QH14016, 04DZ14901).
Supporting Information Available: Experimental procedures and
characterizations of new compounds, 1H NMR and 13C NMR spectra,
and tables of NMR data and HPLC comparisons and CIF files for
compounds 11a-d. This material is available free of charge via the
References
(1) (a) Duncan, S. J.; Gruschow, S.; Williams, D. H.; McNicholas, C.; Purewai,
R.; Hajek, M.; Gerlitz, M.; Martin, S.; Wrigley, S. K.; Moore, M. J. Am.
Chem. Soc. 2001, 123, 554-560. (b) Duncan, S. J.; Williams, D. H.;
Ainsworth, M.; Martin, S.; Ford, R.; Wrigley, S. K. Tetrahedron Lett.
2002, 43, 1075-1078.
(2) Duncan, S. J.; Cooper, M. A.; Williams, D. H. Chem. Commun. 2003,
316-317.
(3) For, a review, see: Chene, P. Mol. Cancer Res. 2004, 2, 20-28.
(4) (a) Desai, P.; Pfeiffer, S. S.; Boger, D. L. Org. Lett. 2003, 5, 5047-
5050. (b) Malkinson, J. P.; Zloh, M.; Kadom, M.; Errington, R.; Smith,
P. J.; Searcey, M. Org. Lett. 2003, 5, 5051-5054.
(5) Wei, W.-G.; Yao, Z.-J. J. Org. Chem. 2005, 70, 4585-4590.
(6) (a) Wei, W.-G.; Qian, W.-J.; Zhang, Y.-X.; Yao, Z.-J. Tetrahedron Lett.
2006, 47, 4171-4174. (b) Wei, W.-G., Zhang, Y.-X.; Yao, Z.-J.
Tetrahedron 2005, 61, 11882-11886.
(7) Zhu, J.; Germain, A. R.; Porco, J. A., Jr. Angew. Chem., Int. Ed. 2004,
43, 1239-1243.
(8) Zhu, J.; Grigoriadis, N. P.; Lee, J. P.; Porco, J. A., Jr. J. Am. Chem. Soc.
2005, 127, 9342-9343.
JA072225G
9
J. AM. CHEM. SOC. VOL. 129, NO. 20, 2007 6401